Cargando…

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Fosfomycin is a bactericidal agent that inhibits cell wall synthesis using a mechanism of action distinct from β-lactams or other antimicrobial agents. It is a broad-spectrum agent that is frequently active against antimicrobial-resistant bacterial pathogens including methicillin-resistant Staphyloc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhanel, George G., Zhanel, Michael A., Karlowsky, James A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036856/ https://www.ncbi.nlm.nih.gov/pubmed/30046362 http://dx.doi.org/10.1155/2018/8912039

Ejemplares similares

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli
por: Zhanel, George G., et al.
Publicado: (2018)

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
por: Zhanel, George G., et al.
Publicado: (2016)

Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity
por: Zhanel, George G., et al.
Publicado: (2016)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario
por: Perrault, Louise, et al.
Publicado: (2017)

Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19
por: Zhanel, George G., et al.
Publicado: (2021)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018
por: Walkty, Andrew, et al.
Publicado: (2019)

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa
por: Yang, Xuan, et al.
Publicado: (2018)

128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018
por: Walkty, Andrew, et al.
Publicado: (2019)

In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
por: Walkty, Andrew, et al.
Publicado: (2017)

254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013
por: Walkty, Andrew, et al.
Publicado: (2014)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)
por: Walkty, Andrew, et al.
Publicado: (2017)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020
por: Walkty, Andrew, et al.
Publicado: (2022)

2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017
por: Walkty, Andrew, et al.
Publicado: (2018)

Oral and intravenous fosfomycin in complicated urinary tract infections
por: López-Montesinos, Inmaculada, et al.
Publicado: (2019)

1242. Efficacy and Safety of Intravenous Fosfomycin for the Treatment of Multi-resistant Gram Negative Infections
por: Abdallah, Tasneem, et al.
Publicado: (2021)

1216. Presence of the Narrow-Spectrum OXA-1 Beta-lactamase Enzyme Is Associated with Elevated Piperacillin-Tazobactam MIC Values Among ESBL-producing Escherichia coli Clinical Isolates (CANWARD, 2007-2018)
por: Walkty, Andrew, et al.
Publicado: (2021)

668. Presence of the Narrow-Spectrum OXA-1 Beta-Lactamase Enzyme is not Associated with Elevated Ceftolozane-Tazobactam MIC Values among ESBL-Producing Escherichia coli Clinical Isolates (CANWARD, 2011-2018)
por: Walkty, Andrew, et al.
Publicado: (2022)

Chicken as Reservoir for Extraintestinal Pathogenic Escherichia coli in Humans, Canada
por: Bergeron, Catherine Racicot, et al.
Publicado: (2012)

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae
por: Önal, Uğur, et al.
Publicado: (2023)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia
por: Zhanel, George G, et al.
Publicado: (2006)

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris
por: Zhanel, George, et al.
Publicado: (2018)

Intravenous fosfomycin therapy in critically ill patients infected with colistin-resistant enterobacteriacae
por: Mukherjee, DN, et al.
Publicado: (2015)

Analyzing game statistics and career trajectories of female elite junior tennis players: A machine learning approach
por: Bozděch, Michal, et al.
Publicado: (2023)

Guanidinylated Polymyxins as Outer Membrane Permeabilizers Capable of Potentiating Rifampicin, Erythromycin, Ceftazidime and Aztreonam against Gram-Negative Bacteria
por: Ramirez, Danzel Marie, et al.
Publicado: (2022)

Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand
por: Thampithak, Anusorn, et al.
Publicado: (2022)

Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan
por: Chen, Tzu-Ting, et al.
Publicado: (2023)

Guanidylation and Tail Effects in Cationic Antimicrobial Lipopeptoids
por: Findlay, Brandon, et al.
Publicado: (2012)

Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae
por: Slipski, Carmine J., et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

Fosfomycin: Uses and potentialities in veterinary medicine
por: Pérez, D.S., et al.
Publicado: (2014)

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

The role of fosfomycin in osteoarticular infection
por: Morata, Laura, et al.
Publicado: (2019)

Synthesis and Antibacterial Activities of Amphiphilic Neomycin B-based Bilipid Conjugates and Fluorinated Neomycin B-based Lipids
por: Bera, Smritilekha, et al.
Publicado: (2012)

Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
por: Lagacé-Wiens, Philippe, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jm2rbj549nr9269to4uatu9jfi